Navigation Links
Despite Increasing Cost Sensitivity of EU5 Payers, Sofosbuvir and Simeprevir are Poised to Reshape the Hepatitis C Virus Market by End of 2015
Date:12/9/2013

BURLINGTON, Mass., Dec. 9, 2013  /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed gastroenterologists across the EU5 (France, Germany, Italy, Spain and the United Kingdom) anticipate prescribing Gilead's sofosbuvir to approximately 20 percent of their hepatitis C virus genotype 1 (HCV-1) patients and Janssen/Medivir's simeprevir to approximately 7 percent of these patients by the end of 2015. Surveyed specialists also indicated that they expect to prescribe sofosbuvir-based regimens to more than one-third of their HCV-2 and HCV-3 patients in this timeframe. Additionally, with sofosbuvir anticipated to be the first approved drug not requiring combination usage with interferon (IFN) in HCV-2 and/or HCV-3 patients, surveyed physicians expect that close to two-thirds of sofosbuvir-treated patients will receive it as part of IFN-free regimens by the end of 2015.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

Currently available first-generation protease inhibitors (Janssen's Incivo and Merck/Roche's Victrelis) and pegylated IFNs (Roche's Pegasys and Merck's PegIntron) receive government reimbursement and coverage in the EU5 markets. However, country-specific cost-effectiveness analyses and prescribing parameters that tie guideline adherence to reimbursement are increasingly being implemented and inform physician prescribing practices. These mechanisms demonstrate the growing importance of health technology assessment, value-based pricing and patient access programs and will continue to be key market access hurdles in the evaluation, reimbursement and uptake of all future HCV therapies.

The new European Physician and Payer Forum report entitled The Impending Inteferon-Free Era of Hepatitis C Virus Treatment: How Will All-Oral Regimens Shape EU5 Prescribing, and What Market Access Challenges Will They Face? also finds that individual European markets have implemented varying mechanisms for aggressively promoting the rational use of HCV medicines, including hospital-based prescribing (France), national online registers to track the use of costly therapies (Italy) and reimbursement oversight boards (United Kingdom).

"The revolutionary developments in the treatment of HCV in the coming years will bring to the market tremendous improvements in efficacy, tolerability and convenience of HCV regimens. However, in the cost-constrained EU5 markets, drug developers will need to balance payer authorities' price expectations with uptake potential for maximum return on investment," said Decision Resources Analyst David Holman, Ph.D. "As competition escalates in the HCV market, budget constraints at regional, local and institutional levels must all be carefully considered."

Manufacturers seeking to penetrate the EU5 HCV market must also optimize pivotal trial design, preferably offering head-to-head comparison against currently marketed protease inhibitors, and should provide thorough cost-effectiveness analyses on their products. Such data is increasingly vital in all EU5 countries as cost-constrained healthcare authorities strive to draw out value for money. 

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Despite A Difficult Competitive Environment, Opportunities Can Still Be Found In The Growing US Trauma Fixation Device Market
2. Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
3. ResearchMoz.us: Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
4. Despite the Numerous Agents in Development for the Treatment of Chronic HCV Infections, a Notable Share of Physicians in Europe Lack Awareness of the HCV Pipeline
5. Americas Biopharmaceutical Companies Commitment to Research Remains Strong Despite Challenges
6. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
7. Global Spinal Nonfusion Market to Grow to $1 Billion by 2017, Despite Challenges
8. Opportunities Exist Despite Challenges in Chinas API Market
9. Accelerating Drugs to Market - Despite Challenges, Adaptive Clinical Trials Reduce Drug Development Costs and Time to Market
10. According to New Survey, Most Men are Not Proactive about Their Health Despite the Desire to Live Long Lives
11. Surveyed Oncologists Indicate that the Use of Biomarker Testing is Increasing Rapidly in Non-Small-Cell Lung Cancer in China and South Korea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)...  Astellas Pharma Inc. President and Chief Executive Officer ... Robinson as president, Americas Operations, for Astellas US LLC, ... South America , effective April 1, 2016.  Robinson ... organization in the United States -- ... Yoshida , who is retiring in June 2016.  ...
(Date:2/8/2016)... BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA:CTIC) today announced ... Food and Drug Administration (FDA) on February 4, 2016, ... on the clinical studies being conducted under the Company,s ... hold impacts part of the clinical work currently being ... clinical trials. --> ...
(Date:2/5/2016)... Feb. 5, 2016  Redwood Scientific Technologies, Inc. announced ... designed to help women balance their hormones. This product ... Jason Cardiff , President and CEO. ... to help the millions of women across the country ... of imbalanced hormones. Our research and development team is ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... , ... Delta Dental of California and its affiliated companies announced today that ... who recently retired as president and CEO of Delta Dental of California and its ... Year , helped lead the effort to raise funds for studies to strengthen pancreatic ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... wide variety of organizations. DocuSyst provides a cloud hosted environment for FileHold ... installations include integration with various 3rd party applications using the FileHold web services ...
(Date:2/8/2016)... ... , ... TopConsumerReviews.com recently awarded their highest five-star rating to a product from ... a cluster of melanin when exposed to sunlight. Although most moles are benign and ... embarrassment. Historically, mole removal has involved a painful, often expensive visit to ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... four states in the U.S. require dental technicians to be certified or obtain ... dental industry, NADL created the “What’s In Your Mouth?” campaign to inform dentists ...
(Date:2/7/2016)... Scottsdale, AZ (PRWEB) , ... February 07, 2016 ... ... & Neck and Facial Plastics, has added Kybella® to his medical and surgical ... is a newly approved FDA injectable medication used as a non-surgical alternative for ...
Breaking Medicine News(10 mins):